Details for Patent: 8,729,030

Title:	Peptides that bind to the erythropoietin receptor
Abstract:	The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
Inventor(s):	Holmes; Christopher P. (Saratoga, CA), Yin; Qun (Palo Alto, CA), Lalonde; Guy (Woodside, CA), Schatz; Peter J. (Cupertino, CA), Tumelty; David (San Diego, CA), Balu; Palani (Cupertino, CA), Zemede; Genet (San Jose, CA)
Assignee:	Affymax, Inc. (Palo Alto, CA)
Filing Date:	Nov 12, 2010
Application Number:	12/945,687
Claims:	1. A compound, or a pharmaceutically acceptable salt thereof, comprising: (a) a first peptide monomer and a second peptide monomer, said first and second peptide monomer having the same amino acid sequence selected from the group consisting of (AcG)GLYACHMGPIT(1-nal)VCQPLRK (SEQ ID NO:1) and (AcG)GLYACHMGPIT(1-nal)VCQPLR(MeG)K (SEQ ID NO:2); (b) a linker moiety having the chemical structure --C.sup.1O--CH.sub.2--X--CH.sub.2--C.sup.2O-- wherein (i) C.sup.1O forms an amide bond with an .epsilon.-amino group of C-terminal lysine in the first peptide monomer, (ii) C.sup.2O forms an amide bond with an .epsilon.-amino group of C-terminal lysine in the second peptide monomer, and (iii) X has the chemical structure NCO--(CH.sub.2).sub.2--N.sup.1H-- or ##STR00085## in which N.sup.1 and N.sup.2 of X are each covalently attached to a moiety comprising at least one polyethylene glycol (PEG) molecule. 2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, in which X has the chemical structure NCO--(CH.sub.2)--N.sup.1H and N.sup.1 of X is covalently attached to a PEG molecule via a carbamate linkage. 3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, in which X has the chemical structure NCO--(CH.sub.2)--N.sup.1H-- and N.sup.1 of X is covalently attached to a PEG molecule via an amide linkage. 4. The compound according to claim 1 having the formula: ##STR00086## or a pharmaceutically acceptable salt thereof, wherein: (i) each peptide monomer (AcG)-G-L-Y-A-C-H-M-G-P-I-T-(1-Nal)-V-C-Q-P-L-R is represented by SEQ ID NO:14; (ii) each peptide monomer of the peptide dimer contains an intramolecular disulfide bond between two cysteine (C) residues; and (iii) [PEG] represents a moiety comprising one or more PEG molecules. 5. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, in which each PEG molecule has a molecular weight of about 10,000 to about 50,000 Daltons. 6. The compound according to claim 5, or a pharmaceutically acceptable salt thereof, in which each PEG molecule has a molecular weight of about 20,000 Daltons. 7. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, in which X has the chemical structure ##STR00087## and further comprising carbamate linkages covalently attaching each of N.sup.1 and N.sup.2 of X to at least one PEG molecule. 8. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, said compound having the formula: ##STR00088## wherein: each PEG comprises a linear polyethylene glycol (PEG) molecule having a molecular weight of about 10,000 to about 50,000 Daltons. 9. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, said compound having the formula: ##STR00089## wherein: (i) each peptide monomer (AcG)-G-L-Y-A-C-H-M-G-P-I-T-(1-Nal)-V-C-Q-P-L-R-(MeG) is represented by SEQ ID NO:3; and (ii) each PEG comprises a linear polyethylene glycol (PEG) molecule having a molecular weight of about 10,000 to about 30,000 Daltons. 10. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, in which X has the chemical structure ##STR00090## and further comprising amide linkages covalently attaching each of N.sup.1 and N.sup.2 of X to at least one PEG molecule. 11. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, said compound having the formula: ##STR00091## wherein: each PEG comprises a linear polyethylene glycol (PEG) molecule having a molecular weight of about 10,000 to about 50,000 Daltons. 12. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, said compound having the formula: ##STR00092## wherein: (i) each peptide monomer (AcG)-G-L-Y-A-C-H-M-G-P-I-T-(1-Nal)-V-C-Q-P-L-R-(MeG) is represented by SEQ ID NO:3; and (ii) each PEG comprises a linear polyethylene glycol (PEG) molecule having a molecular weight of about 10,000 to about 30,000 Daltons. 13. The pharmaceutically acceptable salt of a compound according to any of claims 1, 8-9 and 11-12, wherein the pharmaceutically acceptable salt is an acetate salt. 14. A pharmaceutical composition which comprises a pharmaceutically acceptable salt of a compound according to any of claims 1, 8-9 and 11-12, and at least one pharmaceutically acceptable carrier or excipient. 15. A pharmaceutical composition according to claim 14, wherein the pharmaceutically acceptable salt is an acetate salt. 16. A method for treating a patient having a disorder characterized by a deficiency of erythropoietin or by a low or defective red blood cell population, wherein the method comprises administering, to the patient, a therapeutically effective amount of a pharmaceutically acceptable salt of the compound according to any of claims 1, 8-9 and 11-12. 17. The method of claim 16, wherein the disorder is selected from the group consisting of: end stage renal failure or dialysis, beta-thalassemia, cystic fibrosis, spinal cord injury, acute blood loss, aging and neoplastic disease states accompanied by abnormal erythropoiesis. 18. The method of claim 16, wherein the disorder is anemia. 19. The method of claim 18, wherein the anemia is selected from the group consisting of anemia associated with AIDS, auto immune disease or malignancy; early anemia of prematurity; anemia associated with chronic inflammatory disease; and anemia associated with chronic kidney disease. 20. The method of claim 18, wherein the anemia is associated with chronic kidney disease. 21. The method of claim 18, wherein the anemia is associated with a malignancy. 22. A method for treating a patient having a disorder characterized by a deficiency of erythropoietin or by a low or defective red blood cell population, wherein the method comprises administering, to the patient, a pharmaceutical composition according to claim 14.